In the first quarter, the Lazard US Equity Concentrated Portfolio underperformed its benchmark, the S&P 500 Index. Read more here.

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 Conference Call and Webcast. At this time all participants are in a ...

Payer coverage for SUNOSI across all channels is approximately 83% of all ... and 5-HT 1A agonist being developed for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive ...

Payer coverage for SUNOSI across all channels is approximately ... for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) with EDS, binge eating ...

“The first quarter was strong and eventful, with the approval of SYMBRAVO for the acute treatment of migraine, continued growth of AUVELITY and SUNOSI ... results in ADHD and MDD, and progress ...

Two excellent candidates are Vertex Pharmaceuticals ( VRTX -1.05%) and Axsome Therapeutics ( AXSM -1.06%). Here's what makes ...

Sunosi’s net product sales were $25.2 million ... III studies for treating attention deficit hyperactivity disorder (ADHD) and MDD. The company announced top-line data from the phase III ...

Axsome Therapeutics Inc (AXSM) reports a 62% revenue surge, driven by strong product sales and strategic pipeline developments, despite a net loss in Q1 2025.

but I wanted to shift now to Sunosi Sure. Solriamfetol. You guys had two different phase three trials readout in short order. Maybe starting with ADHD, you know, positive data there. Next steps ...